Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10, 2013, in New Orleans, Louisiana.
“These are early results, but they are promising,” said the study’s lead author, Ayalew Tefferi, MD, a hematologist at Mayo Clinic in Rochester, Minnesota. “Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease.”
Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue, and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1, and spliceosome pathway mutations.
“Typically, myelofibrosis is characterized by marrow scarring and, although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow,” Tefferi said. “Some patients in our trial have reverted back to normal bone marrow.”
Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.
Researchers studied imetelstat in 33 patients at the Mayo Clinic and have now followed the first 22 patients for a minimum of 6 months. Among the 22 patients, five achieved complete or partial remissions, including reversal of bone marrow fibrosis in four of these patients. Two of the five patients with complete or partial remission also experienced complete molecular remissions. The overall response rate was 41%.